Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Thoratec CEO Recollects HeartMate Reimbursement Planning Experience

This article was originally published in The Gray Sheet

  • News

Executive Summary

Device companies seeking national coverage decisions should initiate discussions with CMS concerning the economic impact of their new technology, according to Thoratec President & CEO Keith Grossman

You may also be interested in...



Thoratec Projects Market Growth As CMS Revamps VAD Coverage Criteria

Thoratec anticipates that the market for HeartMate will expand if CMS revises its standards for facilities that implant ventricular assist devices (VAD) as a destination therapy, a company official said

Thoratec Projects Market Growth As CMS Revamps VAD Coverage Criteria

Thoratec anticipates that the market for HeartMate will expand if CMS revises its standards for facilities that implant ventricular assist devices (VAD) as a destination therapy, a company official said

Permanent LVAD Implants Appropriate For End-Stage Heart Failure – CMS

Left-ventricular assist device implants for destination therapy will be limited to 60 U.S. centers under the terms of a positive CMS national coverage determination for the therapy, Thoratec estimates

Table

View full table

Tags:
Latest Headlines

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

UK MHRA Updates Assistive Tech And Borderline Regulations

See All
UsernamePublicRestriction

Register

MT021742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By